Drug Profile


Alternative Names: MORAb-004; Ontecizumab

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Ludwig Institute for Cancer Research; Morphotek
  • Developer Morphotek; National Cancer Institute (USA)
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD248 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer; Malignant melanoma; Soft tissue sarcoma
  • Phase I Lymphoma; Solid tumours

Most Recent Events

  • 01 Oct 2016 Eisai completes a phase I trial in Solid tumours (Monotherapy, Second-line therapy or greater) in Japan (NCT01773434)
  • 01 Aug 2016 Morphotek completes a phase II trial in Soft tissue sarcoma (Combination therapy, Metastatic disease) in USA, Australia, Belgium, France, Italy and the Netherlands (NCT01574716)
  • 09 Jun 2015 Phase-II development for colorectal cancer, melanoma and soft tissue sarcoma is ongoing in the US, Australia and the EU
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top